Real-World Evidence on Levetiracetam-Induced Hypokalemia: An Active Comparator Cohort Study
Drugs - Real World Outcomes · 2024-06 · 11 (2) · 331-339
DOI: 10.1007/s40801-024-00431-4 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Drugs - Real World Outcomes, online erschienen am 03.06.2024. Verfasst von Ohoud Almadani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Saudi Food and Drug Authority, Riyadh, Saudi Arabia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: Levetiracetam is an anti-seizure medication (ASM) with an established safety profile. However, a potential safety signal of hypokalemia following levetiracetam use was published in the World Health Organization newsletter. OBJECTIVE: To investigate the possible causal association between the use of levetiracetam and the development of hypokalemia. METHOD: This was a new-user, active-comparator retrospective cohort study using Real-world Evidence Research Network data at the Saudi Food and Drug Authority from 2016 to 2022. Adults (≥ 18 years old) with an incident prescription for either levetiracetam or carbamazepine were followed for up to 6 months from the prescription date. Hypokalemia was ascertained by using diagnostic code (i.e., E87.6) or by serum potassium level below 3.5 mmol/L. A Cox proportional hazards model, adjusted with stabilized inverse probability of treatment weight, was fitted to compare the hazard of hypokalemia between levetiracetam and carbamazepine exposed patients. RESULTS: A total of 8,982 patients entered the study cohort. The incidence rate of hypokalemia was 303 cases per 10,000 patient-years in the levetiracetam-exposed cohort compared to 57 cases per 10,000 patient-years among carbamazepine users. Compared to carbamazepine users, patients exposed to levetiracetam had an adjusted hazard ratio related to induced hypokalemia of 1.99 (95% confidence interval, 0.88-4.49). Results of sensitivity analyses were comparable to the main analysis. CONCLUSION: The hazard ratio for hypokalemia with the use of levetiracetam versus carbamazepine was statistically comparable. However, the potential association between levetiracetam use and hypokalemia cannot be ruled out given the elevated hazard ratios from the main and sensitivity analyses. Further studies may provide a more precise assessment of this association.
Autor:innen und Institutionen
- Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
- Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
- King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
- Pharmaceutical Care Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
- Saudi Food and Drug Authority, Riyadh, Saudi Arabia. aarwisan@sfda.gov.sa.
Zitieren
APA
Almadani, O., Alroba, R., Alfakhri, A., Almohareb, S., Althunian, T., & Alrwisan, A. A. (2024). Real-World Evidence on Levetiracetam-Induced Hypokalemia: An Active Comparator Cohort Study. Drugs - Real World Outcomes, 11(2), 331-339. https://doi.org/10.1007/s40801-024-00431-4
Vancouver
Almadani O, Alroba R, Alfakhri A, Almohareb S, Althunian T, Alrwisan AA. Real-World Evidence on Levetiracetam-Induced Hypokalemia: An Active Comparator Cohort Study. Drugs - Real World Outcomes. 2024;11(2):331-339. doi:10.1007/s40801-024-00431-4
BibTeX
@article{Almadani2024,
author = {Almadani, Ohoud and Alroba, Raseel and Alfakhri, Almaha and Almohareb, Sumaya and Althunian, Turki and Alrwisan, Adel A},
title = {Real-World Evidence on Levetiracetam-Induced Hypokalemia: An Active Comparator Cohort Study},
journal = {Drugs - Real World Outcomes},
year = {2024},
volume = {11},
number = {2},
pages = {331--339},
doi = {10.1007/s40801-024-00431-4}
}
EUVIMED